Related Experiment Video
Updated: Aug 19, 2025

Synthesis of Immunotargeted Magneto-plasmonic Nanoclusters
Published on: August 22, 2014
Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with
Yuchen Xiao1, Tianchuan Zhu2, Qi Zeng3
1Center for Infection and Immunity, Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, China; Southern Marine Science and Engineering Guangdong Laboratory, Zhuhai, Guangdong 519000, China.
Abstract:
Immune checkpoint blockade therapy targeting programmed death-1 (PD-1) or its major ligand programmed death-ligand 1 (PD-L1) has achieved remarkable success in the treatment of several tumors, including colorectal cancer. However, the efficacy of PD-1/PD-L1 inhibitors is limited in some colorectal cancers within the immunosuppressive tumor microenvironment (such as when there is a lack of immune cell infiltration). Herein, anti-PD-L1 functionalized biomimetic polydopamine-modified gold nanostar nanoparticles (PDA/GNS@aPD-L1 NPs) were developed for synergistic anti-tumor treatment by combining PD-1/PD-L1 blockade with photothermal ablation. PDA/GNS@aPD-L1 NPs were prepared by encapsulating photothermal nanoparticles (polydopamine-modified gold nanostar, PDA-GNS) with cell membrane isolated from anti-PD-L1 single-chain variable fragment (scFv) over-expressing cells. In addition to disrupting PD-1/PD-L1 immunosuppressive signals, the anti-PD-L1 scFv on the membrane of PDA/GNS@aPD-L1 NPs was conducive to the accumulation of PDA-GNS at tumor sites. Importantly, the tumor photothermal ablation induced by PDA-GNS could reverse the immunosuppressive tumor microenvironment, thereby further improving the efficiency of PD-1/PD-L1 blockade therapy. In this study, the synthetized PDA/GNS@aPD-L1 NPs exhibited good biocompatibility, efficient photothermal conversion ability, and enhanced tumor-targeting ability. In vivo studies revealed that a PDA/GNS@aPD-L1 NP-based therapeutic strategy significantly inhibited tumor growth, and prolonged overall survival by further promoting the maturation of dendritic cells (DCs), increasing the infiltration of CD8+T cells, and decreasing the number of immunosuppressive cells (such as regulatory T cells and myeloid-derived suppressive cells). Collectively, the developed PDA/GNS@aPD-L1 NP-based therapeutic strategy combines PD-1/PD-L1 blockade with photothermal ablation, which could remodel the tumor microenvironment for effective clinical colorectal cancer therapy. STATEMENT OF SIGNIFICANCE: Immunosuppressive tumor microenvironment is the main challenge facing programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) blockade therapy. By encapsulating photothermal nanoparticles (polydopamine-modified gold nanostar, PDA-GNS) with cell membrane over-expressing anti-PD-L1 single-chain variable fragment, we constructed anti-PD-L1 functionalized biomimetic nanoparticles (PDA/GNS@aPD-L1 NPs). By specific binding to the PD-L1 present on tumor cells, PDA/GNS@aPD-L1 NPs could disrupt PD-1/PD-L1 immunosuppression signaling, and effectively deliver PDA-GNS targeting to tumor sites. Additionally, PDA-GNS-mediated local photothermal ablation of tumors promoted the release of tumor-associated antigens and thus activated anti-tumor immune responses. Meanwhile, hyperthermia facilitates immune cell infiltration by increasing tumor vascular permeability. Therefore, PDA/GNS@aPD-L1 NPs could sensitize tumors to PD-1/PD-L1 blockade therapy by remodeling the immunosuppressive tumor microenvironment, which provides a new strategy for tumor treatment.
Insights
This study developed novel nanoparticles combining PD-1/PD-L1 blockade with photothermal therapy to overcome colorectal cancer's immunosuppressive tumor microenvironment. This synergistic approach enhances anti-tumor immunity and improves treatment efficacy.
Area of Science:
- Nanotechnology and Cancer Therapy
- Immunooncology
- Biomedical Engineering
Background:
- Immune checkpoint inhibitors targeting PD-1/PD-L1 show success in colorectal cancer but are limited by immunosuppressive tumor microenvironments.
- Lack of immune cell infiltration in tumors hinders the efficacy of current PD-1/PD-L1 blockade therapies.
Purpose of the Study:
- To develop novel biomimetic nanoparticles for synergistic anti-tumor treatment.
- To combine PD-1/PD-L1 blockade with photothermal ablation to remodel the tumor microenvironment.
- To enhance the efficacy of colorectal cancer therapy.
Main Methods:
- Developed anti-PD-L1 functionalized polydopamine-modified gold nanostar nanoparticles (PDA/GNS@aPD-L1 NPs).
- Encapsulated photothermal nanoparticles (PDA-GNS) within cell membranes from anti-PD-L1 scFv over-expressing cells.
- Evaluated nanoparticle biocompatibility, photothermal conversion, tumor targeting, and in vivo anti-tumor effects.
Main Results:
- PDA/GNS@aPD-L1 NPs demonstrated good biocompatibility, efficient photothermal conversion, and enhanced tumor targeting.
- In vivo studies showed significant tumor growth inhibition and prolonged survival.
- Therapeutic strategy promoted dendritic cell maturation, increased CD8+ T cell infiltration, and reduced immunosuppressive cells.
Conclusions:
- The developed PDA/GNS@aPD-L1 NP-based strategy effectively combines PD-1/PD-L1 blockade with photothermal ablation.
- This approach successfully remodels the immunosuppressive tumor microenvironment, enhancing anti-tumor immune responses.
- This offers a promising new therapeutic strategy for colorectal cancer treatment.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...

